Newsroom - Page 11

A letter from CMS Acting Administrator Andy Slavitt that was made public said that Mylan had been warned repeatedly that it was not using the right classification for the EpiPen, at taxpayers' expense.
What we're reading, October 10, 2016: Anthem will not cover Exondys 51, the first drug approved for treatment of Duchenne muscular dystrophy; big soda has sponsored 96 health and medical groups; and new Illinois program seeks to fill care gaps for working poor.
While previous studies have revealed concerning issues regarding workplace wellness programs, the industry has now crossed a line. The program chosen as the industry's best actually harmed employees.
While nivolumab failed to surpass the outcomes of chemotherapy as first-line treatment in programmed death ligand-1–expressing patients with non-small cell lung cancer (NSCLC), pembrolizumab bettered chemotherapy in improving survival in a similar cohort.
As part of the National Comprehensive Cancer Network's new clinical guidelines for myeloproliferative neoplasms, a group of rare blood cancers, Jakafi has been recommended for the treatment of myelofibrosis.
A large majorities of Americans favor a wide range of policy changes to curb prescription drug costs, including those that give government a greater role in negotiating or limiting drug prices, according to the latest Kaiser Family Foundation Health Tracking Poll.
Cost sharing for hospitalizations among nonelderly adults increased 37% between 2009 and 2013, more than the rate of medical inflation, according to a review of national hospital claims from 3 major commercial insurance plans.
Although hospitals in Medicare’s Value-Based Purchasing program already receive patient experience points based on achievement, improvement, and consistency, placing more emphasis on improvement points could benefit hospitals serving minority patients
Diabetes Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium